1. Home
  2. KEQU vs MOLN Comparison

KEQU vs MOLN Comparison

Compare KEQU & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kewaunee Scientific Corporation

KEQU

Kewaunee Scientific Corporation

N/A

Current Price

$34.70

Market Cap

106.6M

Sector

Industrials

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.34

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEQU
MOLN
Founded
1906
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
106.6M
158.9M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
KEQU
MOLN
Price
$34.70
$4.34
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
6.1K
2.9K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.09
N/A
Revenue
$138,558,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$318.52
P/E Ratio
$18.95
N/A
Revenue Growth
7.72
N/A
52 Week Low
$30.33
$3.36
52 Week High
$60.89
$5.36

Technical Indicators

Market Signals
Indicator
KEQU
MOLN
Relative Strength Index (RSI) 31.40 42.13
Support Level N/A $3.50
Resistance Level $41.84 $4.63
Average True Range (ATR) 1.34 0.25
MACD -0.85 -0.09
Stochastic Oscillator 5.77 25.40

Price Performance

Historical Comparison
KEQU
MOLN

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: